Pacira BioSciences, Inc. (PCRX) Earnings History
Annual and quarterly earnings data from 2008 to 2025
Loading earnings history...
PCRX EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
PCRX Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 79.4% | 4.6% | 1.0% |
| 2024 | 75.7% | -10.5% | -14.2% |
| 2023 | 72.6% | 13.0% | 6.2% |
| 2022 | 70.1% | 9.0% | 2.4% |
| 2021 | 74.1% | 16.6% | 7.8% |
Download Data
Export PCRX earnings history in CSV or JSON format
Free sign-in required to download data
Pacira BioSciences, Inc. (PCRX) Earnings Overview
As of May 8, 2026, Pacira BioSciences, Inc. (PCRX) reported trailing twelve-month net income of $9M, reflecting +107.4% year-over-year growth. The company earned $0.23 per diluted share over the past four quarters, with a net profit margin of 1.0%.
Looking at the long-term picture, PCRX's 5-year EPS compound annual growth rate (CAGR) stands at -45.5%, signaling declining earnings. The company achieved its highest annual net income of $146M in fiscal 2020.
Pacira BioSciences, Inc. maintains positive profitability with a gross margin of 79.4%, operating margin of 4.6%, and net margin of 1.0%. The company continues to generate positive earnings from operations. View revenue history →
Compared to peers including PRGO (-$1.82B net income, -33.5% margin), BHC (-$1.19B net income, 1.5% margin), SUPN (-$29M net income, -5.4% margin), PCRX has outperformed on profitability metrics. Compare PCRX vs PRGO →
PCRX Earnings vs Peers
Earnings metrics vs comparable public companies
PCRX Historical Earnings Data (2008–2025)
18 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $7M | +107.1% | $33M | $0.16 | 1.0% | 4.6% |
| 2024 | -$100M | -337.3% | -$73M | $-2.15 | -14.2% | -10.5% |
| 2023 | $42M | +163.7% | $88M | $0.89 | 6.2% | 13.0% |
| 2022 | $16M | -62.1% | $60M | $0.34 | 2.4% | 9.0% |
| 2021 | $42M | -71.2% | $90M | $0.92 | 7.8% | 16.6% |
| 2020 | $146M | +1421.0% | $46M | $3.33 | 33.9% | 10.8% |
| 2019 | -$11M | -2238.9% | $10M | $-0.27 | -2.6% | 2.5% |
| 2018 | $-471,000 | +98.9% | $16M | $-0.01 | -0.1% | 4.7% |
| 2017 | -$43M | -12.3% | -$25M | $-1.07 | -14.9% | -8.7% |
| 2016 | -$38M | -2144.7% | -$32M | $-1.02 | -13.7% | -11.6% |
See PCRX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PCRX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare PCRX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonPCRX — Frequently Asked Questions
Quick answers to the most common questions about buying PCRX stock.
Is PCRX growing earnings?
PCRX EPS is $0.23, with earnings growth accelerating to +107.4%. This exceeds the 5-year CAGR of -45.5%. TTM net income reached $9M.
What are PCRX's profit margins?
Pacira BioSciences, Inc. net margin is +1.0%, with operating margin at +4.6%. Below-average margins reflect competitive or cost pressures.
How consistent are PCRX's earnings?
PCRX earnings data spans 2008-2025. The accelerating earnings trend is +107.4% YoY. Historical data enables comparison across business cycles.